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BEYOND BIDIL: THE EXPANDING EMBRACE OF RACE IN BIOMEDICAL 
RESEARCH AND PRODUCT DEVELOPMENT 
JONATHAN KAHN* 
I.  INTRODUCTION 
In 2005, the U.S. Food and Drug Administration (FDA) approved the 
drug, BiDil®, for treatment of heart failure in “black” patients.1  The 
approval of this first, and currently only, race-specific drug provoked an 
energetic and sustained discussion of the propriety of using racial categories 
in drug development in a wide array of media and professional journals.2  
BiDil is the prototype of using race as a placeholder during the “meantime” 
of pharmacogenomic development.  As one article in the journal Science 
stated at the time, “By backing BiDil, the FDA panel gave another push to 
pharmacogenomics, an approach that promises to revolutionize both drug 
discovery and patient care.”3 
The 2005 FDA approval was based on results from the African-
American Heart Failure Trial (A-HeFT)4 that were published the previous 
November in the New England Journal of Medicine.5  The trial design itself 
was groundbreaking because it included only self-identified African 
 
* J.D., Ph.D., Professor of Law, Hamline University School of Law.  I would like to thank the 
participants at the Saint Louis University Health Law Symposium: “Living in the Genetic Age,” 
and the participants at the Annual Meeting of the Science and Democracy Network for their 
helpful comments and suggestions.  Work on this article was supported in part by the Ethical, 
Legal, and Social Implications Research Program, National Human Genome Research 
Institute (Grant number R03-HG004034-02). 
 1. News Release, U.S. Food & Drug Admin., FDA Approves BiDil Heart Failure Drug for 
Black Patients (June 23, 2005) [hereinafter FDA News Release], http://www.fda.gov/News 
Events/Newsroom/PressAnnouncements/2005/ucm108445.htm. 
 2. See, e.g., Jonathan Kahn, How a Drug Becomes “Ethnic”: Law, Commerce, and the 
Production of Racial Categories in Medicine, YALE J. HEALTH POL’Y L. & ETHICS, Winter 2004, at 
3, 33 (discussing the use of race in the development of BiDil).  See also Timothy Caulfield & 
Simrat Harry, Popular Representations of Race: The News Coverage of BiDil, 36 J.L. MED. & 
ETHICS 485, 485-86 (2008) (reporting that when the term “BiDil” was searched in the Lexis-
Nexis database it yielded a total of 167 U.S. newspaper articles). 
 3. Robert F. Service, Going from Genome to Pill, 308 SCIENCE 1858, 1858 (2005). 
 4. FDA News Release, supra note 1. 
 5. See Anne L. Taylor et al., Combination of Isosorbide Dinitrate and Hydralazine in 
Blacks with Heart Failure, 351 NEW ENG. J. MED. 2049, 2050 (2004). 
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Americans.6  The results therefore give the impression that BiDil works only 
in African Americans.  This is clearly not the case.  The trial investigators 
themselves concede that BiDil will work in people regardless of race.7  
Without a comparison population, the investigators cannot even claim that 
the drug works differently in African Americans than in any other group.8  
Nonetheless, NitroMed, the corporate sponsor of BiDil, applied for and 
received FDA approval for the drug with a race-specific indication to treat 
heart failure only in African Americans.  Pervasive media coverage of the 
announcement of the results and the FDA approval also focused on the 
racial-specificity of the drug, often explicitly claiming that it shows race is 
genetic.9 
Underlying the trial design, however, is a race-specific patent issued by 
the United States Patent and Trademark Office (PTO) on October 15, 
2002, that is premised on a biological or genetic conception of race.10  It 
confers intellectual property protection for the method of using the drug to 
treat heart failure in African Americans until 2020.11  A previous patent 
issued in 1987 to the same inventor for the same method of using the same 
drug in the general population without regard to race expired in 2007.12  
Therefore, in this case, bringing race into the patent system allowed the 
inventor to gain a substantial extension of his intellectual property 
monopoly. 
Both the patent and the drug trial for BiDil relate their race-specific 
design to a search for genetic markers underlying heart disease.  On the 
 
 6. Id. 
 7. See Denise Gellene, Heart Pill Intended Only for Blacks Sparks Debate, L.A. TIMES, 
June 16, 2005 at C1 (reporting that trial investigator and cardiologist Jay N. Cohn prescribes 
the generic drugs that make up BiDil to white patients as well, saying “I actually think 
everybody should be using it.”). 
 8. Id. 
 9. See Jonathan Kahn, Misreading Race and Genomics after BiDil, 37 NATURE GENETICS 
655, 655 (2005) [hereinafter Kahn, Misreading Race]. 
 10. Methods of Treating & Preventing Congestive Heart Failure with Hydralazine 
Compounds & Isosorbide Dinitrate or Isosorbide Mononitrate, U.S. Patent No. 6,465,463 
(filed Sept. 8, 2000) (issued Oct.15, 2002). 
 11. Id.; U.S. Patent & Trademark Office, General Information Concerning Patents (Jan. 
2005), http://www.uspto.gov/web/offices/pac/doc/general/index.html (explaining that the 
term of a new patent in the United States is 20 years from the date on which the patent 
application was filed).  See also Kahn, Misreading Race, supra note 9, at 655 (noting that 
NitroMed, Inc. also “holds a patent for a non-race-specific use of BiDil” that expires in 2007). 
 12. Method of Reducing Mortality Associated with Congestive Heart Failure Using 
Hydralazine & Isosorbide Dinitrate, U.S. Patent No. 4,868,179 (filed Apr. 22, 1987) (issued 
Sept. 19, 1989).  See also Jonathan Kahn, From Disparity to Difference: How Race-Specific 
Medicines May Undermine Policies to Address Inequalities in Health Care, 15 S. CAL. 
INTERDISC. L.J. 105, 112 (2005) (noting that through receiving a new, race-based patent, 
NitroMed extended their monopoly on BiDil). 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
2009] BEYOND BIDIL 63 
one hand, this reflects an approach, largely sanctioned by many in the 
emerging field of pharmacogenomics,13 of using race instrumentally as a 
surrogate to get at underlying genetic variation that could be ultimately 
identified without reference to race.  On the other hand, for the foreseeable 
future, it presents the immediate reality of race being used as a quasi-
genetic category to obtain patents and drug approvals and to increase 
market share. 
The question then becomes, is BiDil an anomaly or a harbinger of things 
to come?  The answer, it turns out, is a little of both.  This article will 
consider two prominent and recent examples of the continued use of race in 
biomedical research and product development.  The first is the beta-blocker 
Bystolic® (nebivolol), a drug used to treat cardiovascular conditions such as 
hypertension.14  It treats similar conditions as BiDil, but is a different class of 
drug.15  Unlike BiDil, Bystolic is not a combination of two generic drugs but 
rather has its own independent patent on the actual composition of matter 
that comprises the drug itself.16  The marketers of Bystolic, however, have 
taken a page from the BiDil playbook, as it were, in using race to 
differentiate their product in a crowded marketplace by mentioning the 
drug’s effect with respect to race in its package insert.17  At this point, there 
are no race-specific patents issued for Bystolic, but several are pending 
before the PTO.18 
The second example of the use of race in biomedical research and 
product development involves the drug warfarin, a widely prescribed blood-
thinning agent.  Warfarin itself is a generic drug and not directly the subject 
 
 13. Wolfgang Sadee, Drug Therapy and Personalized Health Care: Pharmacogenomics 
in Perspective, 25 PHARMACEUTICAL RES. 2713, 2714 (2008) (noting that pharmacogenomics 
incorporates pharmacogenetics—the “study of genetic causes of variability in drug 
response”—in order to fulfill pharmacogenomics’ broader goal of using genetics to aid “drug 
discovery, development, and therapy”).  See also Francis S. Collins, What We Do and Don’t 
Know About ‘Race’, ‘Ethnicity’, Genetics and Health at the Dawn of the Genome Era, 36 NAT. 
GENETICS S13 (2004). 
 14. FOREST PHARMACEUTICALS, INC., BYSTOLIC® (2008) (package insert), available at 
http://www.frx.com/pi/Bystolic_pi.pdf. 
 15. See NITROMED, INC., BIDIL® PACKAGE INSERT (2005), available at http://www.access 
data.fda.gov/drugsatfda_docs/label/2005/020727lbl.pdf. 
 16. Compositions Containing Micronized Nebivolol, U.S. Patent No. 5,759,580 (filed 
Feb. 10, 1995) (issued June 2, 1998). 
 17. See FOREST PHARMACEUTICALS, INC., supra note 14 at 6 (noting that “[e]ffectiveness 
was established in Blacks”). 
 18. See, e.g., Hyroxylated Nebivolol Metabolites, U.S. Patent Application No. 
20070014733 (filed Jan. 18, 2007) (claiming “[a] method of reducing mortality associated 
with cardiovascular disease in a black patient comprising administering to the black patient a 
therapeutically effective amount of . . . nebivolol”).  See also Glucuronidated Nebivolol 
Metabolites, U.S. Patent Application No. 20070014734 (filed Jan. 18, 2007). 
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of race-specific marketing.  In recent years, however, biomedical 
researchers have discovered several specific genetic variations that have a 
significant impact on patient response to warfarin.19  Race becomes a factor 
for warfarin through the field of pharmacodiagnostics—the development of 
tests which identify whether individuals have certain genetic variants that 
may affect drug response.20  In the past several years many companies have 
come forward offering such tests.21  Some studies have shown that these 
genetic variations appear at different frequencies in different racial groups.22  
One company, AutoGenomics, has explicitly embraced such racial variation 
as a basis for distinguishing its product from other genetic tests on the 
market.23  In addition, PharmiGene, a company in Taiwan, reportedly has a 
race-specific patent pending concerning its particular method of testing for 
genetic variations in warfarin response.24  Again, like BiDil, race is being 
used to create market opportunity and gain patent protection; but unlike 
BiDil, we do not specifically see race being used to extend or resurrect 
patent protection for existing products. 
II.  BYSTOLIC: MAKING THE EIGHTEENTH BETA-BLOCKER STAND OUT 
Ethnic niche marketing is well-established in American product 
development and advertising.  Commercial biotechnology seems to have 
discovered the potential of such marketing in the case of BiDil.  It is here 
that the model of BiDil, for all its distinctiveness, has most clearly taken hold.  
Big Pharma is plagued with a plethora of “me-too” products.  Once one 
company develops a particular blockbuster drug, whether in pain relief (e.g. 
Cox-2 inhibitors) or cardiovascular health (e.g. statins), others clamber to 
join the bandwagon by producing biologically similar, yet legally distinct 
(i.e. non-patent-infringing) pharmaceutical products.  With numerous similar 
products on the market, it becomes essential for each producer to try to 
 
 19. See Warfarin, Race, and the Business of Pharmacodiagnostics, infra Part III.  See also 
Ann K. Daly, Pharmacogenomics of Anticoagulants: Steps toward Personal Dosage, 1 
GENOME MED. 10.1, 10.1 (2009). 
 20. See H. Ngow et al., Role of Pharmacodiagnostic of CYP2C9 Variants in the 
Optimization of Warfarin Therapy in Malaysia: A 6-Month Follow-Up Study, 38 XENOBIOTICA 
641, 642-43 (2008). 
 21. See Turna Ray, Competition Heats Up in Warfarin Dx Market as New Tests Seek FDA 
OK, PHARMACOGENOMICS REP., Oct. 10, 2007, http://www.genomeweb.com/dxpgx/ 
competition-heats-warfarin-dx-market-new-tests-seek-fda-ok. 
 22. See infra notes 71-75 and accompanying text. 
 23. See Ray, supra note 21. 
 24. Press Release, Pharmigene Obtains European Patent for Genetic Discovery Predicting 
Warfarin Sensitivity (Mar. 24, 2009), http://pharmalicensing.com/public/press/view/1237856 
381_49c8307dbb1e6/pharmigene-obtains-european-patent-for-genetic-discovery-predicting-
warfarin-sensitivity. 
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distinguish its drug from the competition.  Traditionally, this was done 
through claims of improved efficacy or lesser side effects.  More recently, 
pharmaceutical and medical device companies have discovered race as a 
means to distinguish their products (and patents) as well.  In the realm of 
pharmaceuticals, particularly striking is the beta-blocker, nebivolol, 
marketed as Bystolic by Forest Laboratories. 
Beta-blockers comprise a class of drugs that have been used for 
decades to treat hypertension and other cardiovascular conditions such as 
heart failure.25  There are currently at least eighteen beta-blockers on the 
market, several available as low-cost generics.26  In such a market, it seems 
striking, therefore, that Forest Laboratories would take the time and incur the 
expense to bring yet another beta-blocker to the FDA for approval in 2007.  
Yet this is exactly what it did with nebivolol, a beta-blocker that had been 
used in Europe for over a decade but whose original inventor, Janssen 
Pharmaceutical NV, had never sought to bring it to the American market.27  
Forest received approval for nebivolol in December, 2007 and began 
marketing it as Bystolic shortly thereafter.28  In numerous press releases and 
discussions of funded clinical research, Forest and its surrogates (including 
the doctors conducting Forest-sponsored clinical trials) emphasized two key 
aspects of Bystolic’s profile in order to differentiate it from the other 
seventeen beta-blockers on the market:  First, it has fewer side effects—in 
particular, fewer incidences of erectile dysfunction;29 and second, it worked 
well in African Americans in a drug trial.30  This latter claim is particularly 
significant because there has been ongoing debate in the medical literature 
about the relative efficacy of beta-blockers in self-identified African-
 
 25. See generally Michael B. Fowler, Hypertension, Heart Failure, and Beta-Andrenergic 
Blocking Drugs, 52 J. AM. C. CARDIOLOGY 1073, 1073 (2008) (commenting on the use of 
beta-blockers for hypertension and heart failure). 
 26. Brian Orelli, New Beta Blocker on the Crowded Street, MOTLEY FOOL, Dec. 17, 
2007, http://www.fool.com/investing/dividends-income/2007/12/19/new-beta-blocker-in-a-
crowded-forest.aspx. 
 27. See Press Release, Forest Laboratories, Inc., Bystolic™, a Novel Beta Blocker, Is Now 
Approved by the FDA for the Treatment of Hypertension (Dec. 18, 2007), http://www.frx.com/ 
news/PressRelease.aspx?ID=1088188. 
 28. See id. 
 29. Press Release, Forest Laboratories, Inc., Nebivolol Lowers Blood Pressure in Mild-to-
Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of 
Clinical Hypertension (Sept. 4, 2007), http://www.frx.com/news/PressRelease.aspx?ID=104 
7743. 
 30. Press Release, Forest Laboratories, Inc., UPDATE: Nebivolol Lowers Blood Pressure in 
African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the 
Journal of Clinical Hypertension (Nov. 1, 2007), http://www.frx.com/news/PressRelease.aspx? 
ID=1071168. 
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American patient populations.31  Being able to make affirmative claims 
about the efficacy of Bystolic in African Americans thus immediately 
distinguished it from the pack of other beta-blockers.  Forest Laboratories 
made this claim based on a race-specific drug trial, mimicking in many 
respects the A-HeFT trial for BiDil that tested Bystolic exclusively in self-
identified African Americans.32 
As Doctor Elijah Saunders stated in reporting the results of this race-
specific study, “There is a perception that beta blockers are not effective in 
blacks.  But this study refutes that idea.”33  Dr. Paul Underwood, a Phoenix 
cardiologist and President of the Association of Black Cardiologists (which 
co-sponsored the A-HeFT trial with NitroMed) praised the nebivolol study, 
stating, “We’re excited to add another therapeutic tool to the 
armamentarium in the treatment of high blood pressure in African-
Americans.”34  An article on the study in the web-based journal MedScape 
Today, quoted Saunders as stating that 
The findings of this study are important considering the excessive burden of 
high blood pressure in African Americans and the need for new treatment 
options . . . Advances like this in the beta blocker class are particularly 
important because African Americans have a historically poor response to 
beta blocker therapy for hypertension.35 
The article went on to note that “[d]ata suggesting that beta-blockers as a 
class are less effective than other agents in black patients, as well as the 
association with poor tolerability and adverse metabolic effects, have led to 
underuse of traditional beta-blockers in black patients.”36  What is striking 
here is the juxtaposition of the concepts of efficacy and underuse.  
“Underuse” implies that more blacks should be using beta-blockers but do 
not.  The tension here is that if blacks “have a historically poor response to 
beta blockers,” then lesser use is not “underuse,” but rather simply reflects 
 
 31. See, e.g., Sidney Goldstein, Beta Blocker Therapy in African American Patients with 
Heart Failure, 9 HEART FAILURE REVIEWS 161, 161 (2004).  See also Paul G. Shekelle et al., 
Efficacy of Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers in the Management of 
Left Ventricular Systolic Dysfunction According to Race, Gender, and Diabetic Status: A Meta-
Analysis of Major Clinical Trials, 41 J. AM. C. CARDIOLOGY 1529, 1529 (2003); Clyde W. 
Yancy, Race-Based Therapeutics, 10 CURRENT HYPERTENSION REP. 276, 276 (2008). 
 32. See Elijah Saunders et al., The Efficacy and Tolerability of Nebivolol in Hypertensive 
African American Patients, 9 J. CLINICAL HYPERTENSION 866, 867 (2007). 
 33. Daily News Central, Beta Blocker Controls High Blood Pressure in Blacks (July 18, 
2005), http://health.dailynewscentral.com/content/view/1308/63. 
 34. Id. 
 35. Linda Brookes, New Drug Algorithms, New Drug Approvals, New Drugs: New Data 
Reported as Nebivolol Moves Toward Launch in the United States, MedScape.com (Jan. 17, 
2008), http://www.medscape.com/viewarticle/568786_4 (emphasis added). 
 36. Id. (emphasis added). 
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an appropriate level of use due to differential response.  As framed here, the 
advance seems to be as much about opening up the beta-blocker market to 
greater use by blacks as to finding a distinctive new therapy—or rather, the 
distinctiveness of the therapy opens up the market.  In this regard, the 
purportedly poor response of blacks to beta-blockers becomes a market 
opportunity. 
In February of 2008, Dr. Saunders gave a presentation on Bystolic to 
pharmacists in Pennsylvania titled, “The Treatment of Hypertension in the 
Very Tough to Treat Patient (obese, diabetic, African-American).”37  The 
promotional material emphasizes that “Bystolic is a totally unique and novel 
Beta-Blocker that is cardio selective and is a vasodilator.”38  Here the 
promoters of Bystolic have linked novelty, difficulty, and race.  The typical 
“tough” patient is African American.  On one hand, the presentation clearly 
aims at helping a racially identified population that might need better 
therapy.  Dr. Saunders, himself African American, is a distinguished 
professor of Medicine at the University of Maryland and has demonstrated 
over his long career a commitment to helping improve the health of minority 
communities.39  On the other hand, the presentation frames African 
Americans as a problem, akin to such undesirable physical states as obesity 
and diabetes.  The presentation does not simply link Bystolic to race, it 
implies it will make a “tough” racial group, African Americans, not only 
more treatable but more tractable—i.e. less “tough.”  All this as a means 
not simply to promote Bystolic, but to differentiate it from what other beta-
blockers on the marker can (or cannot) do. 
The positive results from the African-American nebivolol trial have 
provided the basis for its marketing claims and also for two race-specific 
patent applications currently pending before the U.S. Patent and Trademark 
Office.40  These patent applications, however, are not quite the same as the 
patents related to BiDil.  They are rather hybrids, containing claims 
regarding the efficacy of nebivolol in a general population early on, and 
then later adding race-specific claims pertaining to a particular type of 
efficacy in “black patient[s].”41  Thus, they are both affirmatively used to 
claim specific racialized territory of intellectual property, but also used 
defensively, by adding a concentric ring of protection to the battlements of 
 
 37. PA Pharmacists Ass’n, Invitation to Program on Bystolic (Feb. 14, 2008), available at 
www.papharmacists.com/2-14-08_%20a%20program%20on%20Bystolic.doc. 
 38. Id. (emphasis added). 
 39. See Maryland Heart Center, Heart Center Physician Biographies, http://www.umm. 
edu/heart/biographies.htm#Saunders (last visited Jan. 06, 2010). 
 40. See U.S. Patent Application 20070014733 and U.S. Patent Application 
20070014734, supra note 18. 
 41. See id. 
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the larger patent.  (The idea being that if a broader claim is challenged—
e.g. the use of nebivolol in a “human”—a narrower claim may survive— 
e.g. the use of nebivolol in a person of “African descent”).  If granted, the 
patents also will provide a legally sanctioned basis for using race to 
distinguish Bystolic in the marketplace.  Thus, in 2008, on a list of the top 
pharmaceutical advertisers in the country, Forest Laboratories moved up 
from number seven to number two.42  The trade journal, Medical Marketing 
and Media noted, Bystolic, at $8.4 million, was the most heavily advertised 
drug in the country during the first half of 2008.43  As Forest Laboratories 
rolls out Bystolic, reports of its race-specific efficacy serve as a critical 
adjunct to its general advertising efforts as it seeks to gain a foothold in the 
crowded beta-blocker market. 
In the latest stage of nebivolol’s journey into race-specific marketing, Dr. 
R. Preston Mason, a consultant to Forest Laboratories,44 led a study 
comparing the effect of nebivolol in “Mexican Americans” to “non-Hispanic 
Whites.”45  Comparing nebivolol against the beta-blocker, atenolol, the 
study concluded that, “[t]reatment with nebivolol, but not atenolol, 
enhanced both the expression and coupling efficiency of eNOS in Mexican 
American endothelium.” 46  That is, race (or here, perhaps more accurately, 
Mexican American/Hispanic ethnicity) is claimed to make a difference in 
nebivolol efficacy, further distinguishing it from other beta-blockers on the 
market. 
Mason was also involved in the earlier African American study of 
nebivolol.47  He is on the faculty of the Harvard Medical School-affiliated 
Brigham and Women’s Hospital in Boston, Massachusetts, and also 
President and Founder of Elucida Research LLC, a private biotechnology 
firm, in Beverly, Massachusetts.48  He now also has a race-specific patent 
application pending before the PTO titled, “Treatment of Cardiovascular 
 
 42. Eugene M. May, The Hits Keep on Coming, MED. MARKETING & MEDIA, Oct. 2008, at 
57, 58 (listing the top spending pharmaceutical companies by advertising dollars). 
 43. Id. at 60. 
 44. theheart.org, Emerging Options for Hypertensive Patients with Osteoarthritis (Aug. 25, 
2009), http://www.theheart.org/article/974377.do. 
 45.  R.P. Mason et al., Nitric Oxide Bioavailability Is Lower in Endothelium of Healthy 
Mexican American Donors as Compared to Non-Hispanic White Donors: Effect of Nebivolol, 
Abstracts from Scientific Sessions 2007, 116 SUPPLEMENT TO CIRCULATION II-295, II-295 
(2007). 
 46. Id. 
 47. See R. Preston Mason et al., Nebivolol Reduces Nitroxidative Stress and Restores 
Nitric Oxide Bioavailability in Endothelium of Black Americans, 112 CIRCULATION 3795, 3795 
(2005), available at http://circ.ahajournals.org/cgi/content/full/112/24/3795. 
 48. 2009 Cardiometabolic Health Congress, Distinguished Faculty, Biography: R. Preston 
Mason, MBA, PhD, http://www.cardiometabolichealth.org/2009/bios/MasonRPreston.asp 
(last visited Jan. 06, 2010). 
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Disease in Mexican Americans Using Nebivolol.”49  Race and ethnicity are 
thus evolving from categories of biomedical research into ways of 
organizing the strategic development of patent portfolios.  The potential 
value of race and ethnicity for generating patents, in turn, provides 
incentives for designing and implementing race-specific clinical trials. 
III.  WARFARIN, RACE, AND THE BUSINESS OF PHARMACODIAGNOSTICS 
Closely related to, but distinct from pharmacogenomic drug 
development is the field of pharmacodiagnostics—the use of genetic testing 
to identify specific genetic variations that affect individual drug response.50  
Pharmacodiagnostics is thus a critical component of the drive toward 
genetically informed personalized medicine.  Being focused on specific 
genes, one might think that race would be even less relevant in this field 
than in drug development.  Yet, here also, race has persisted, and even 
thrived.  Similar to the case of Bystolic, some manufacturers of genetic tests 
have found race to be a useful tool for differentiating their products in a 
crowded marketplace.  A prominent example involves tests developed to 
identify specific genetic variations recently discovered to have a significant 
effect on individual response to the widely prescribed blood-thinning drug 
warfarin (marketed by Bristol-Meyers Squib under the trade name 
Coumadin®).51 
Warfarin, an anticoagulant, is among the most widely prescribed drugs 
in modern medicine.52  In 2004, more than thirty million prescriptions were 
written for the drug in the United States alone.53  Sales of warfarin in the 
U.S. were approximately $500 million in 2002.54  “There was a 1.5-fold 
increase in warfarin prescriptions between 1999 and 2005,”55 perhaps 
reflecting the demographic shift toward an aging population, which is 
typically a primary target of warfarin therapy.  It is commonly prescribed to 
patients who are at risk of developing blood clots, such as persons with 
 
 49. Treatment of Cardiovascular Disease in Mexican Americans Using Nebivolol, U.S. 
Patent Application No. 20090030071 (filed July 15, 2008). 
 50. See H. Ngow, supra note 20, at 642-43. 
 51. See, e.g., PGXL Laboratories, Warfarin, (describing PGXL Laboratories’ 
Pharmacogenetic warfarin test) http://www.pgxlab.com/clinician/warfarin.php (last visited Jan. 
06, 2010). 
 52. Nanogen, Pharmacogenetics and Warfarin Therapy, NEXT GENERATION 
PHARMACEUTICALS, Jan. 2007, http://www.ngpharma.com/article/Pharmacogenetics-and-
warfarin-therapy/. 
 53. Int’l Warfarin Pharmacogenetics Consortium, Estimation of the Warfarin Dose with 
Clinical and Pharmacogenetic Data, 360 NEW ENG. J. MED. 753, 754 (2009). 
 54. Nanogen, supra note 52. 
 55. Myong-Jin Kim et al., A Regulatory Science Perspective on Warfarin Therapy: A 
Pharmacogenetic Opportunity, 49 J. CLINICAL PHARMACOLOGY 138, 139 (2009). 
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atrial fibrillation (a type of abnormal heart beat), recurrent strokes, deep 
venous thrombosis, pulmonary embolism, or those who have received heart 
valve replacements.56  It is difficult to calibrate the correct dose for an 
individual patient because it has a narrow therapeutic window of efficacy 
and a wide-range of inter-individual variability in response.57  Finding a 
correct dosage can be a delicate matter, involving the gradual upward 
titration of an initially low dose with regular monitoring of the coagulation 
rate using the “international normalized ratio” or INR (INR compares the 
blood’s clotting ability at a given moment to a standardized measure) and 
adjusting the dosage until the appropriate rate of coagulation is obtained.58  
Too much warfarin places a patient at risk of developing a potentially fatal 
hemorrhage, while too little may increase the risk of blood clots and 
stroke.59  The complexity of warfarin dosing is indicated by the fact that 
warfarin is the second most common drug (after insulin) implicated in 
emergency room visits, having caused 1,234 emergency room cases in 
2004.60  Further, it is estimated that there are actually over 43,000 adverse 
drug events related to warfarin each year.61 
In the past decade, great strides have been made toward identifying 
specific genetic variations that have significant impacts on individual 
response to warfarin.  Researchers have identified genes responsible for 
producing the enzymes that metabolize warfarin (enzymes that break 
warfarin down and destroy its anticoagulant activity).62  In particular, specific 
polymorphisms in the CYP2C9 gene and VKORC1 gene have been 
identified as accounting for thirty to fifty percent of variation in individual 
warfarin response.63  CYP2C9 affects pharmacokinetics—or what a body 
does to a drug.64  People with certain CYP2C9 alleles that metabolize 
 
 56. See id. at 138. 
 57. Id. 
 58. See Daly, supra note 19, at 10.1. 
 59. U.S. Food & Drug Admin., Critical Path Initiative - Warfarin Dosing (interviewing FDA 
staff involved in pharmacogenetics of warfarin therapy), http://www.fda.gov/ScienceResearch/ 
SpecialTopics/CriticalPathInitiative/FacesBehindCriticalPath/ucm077473.htm (last visited Dec. 
28, 2009).  See Daly, supra note 19, at 10.1-10.4. 
 60. Daniel S. Budnitz et al., National Surveillance of Emergency Department Visits for 
Outpatient Adverse Drug Events, 296 JAMA 1858, 1864 (2006). 
 61. Id. 
 62. See Anna Wilde Mathews, In Milestone, FDA Pushes Genetic Tests Tied to Drug, WALL 
ST. J., Aug. 16, 2007, at A1, available at http://mednews.wustl.edu/clip/page/normal/ 
15608.html. 
 63. M. Teichert et al., Genotypes Associated with Reduced Activity of VKORC1 and 
CYP2C9 and Their Modification of Acenocoumarol Anticoagulation During the Initial 
Treatment Period, 85 CLINICAL PHARMACOLOGY & THERAPEUTICS 379, 379 (2009). 
 64. See Alan HB Wu et al., Dosing Algorithm for Warfarin Using CYP2C9 and VKORC1 
Genotyping from a Multi-Ethnic Population: Comparison with Other Equations, 9 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
2009] BEYOND BIDIL 71 
warfarin more slowly than average would need a lower dose of warfarin.65  
VKORC1, in contrast, involves pharmacodynamics, 66 or “what a drug does 
to a body . . . .”67  Warfarin works, in part, by suppressing the production of 
vitamin K, which is vital to blood clotting.68  Individuals with certain 
VKORC1 alleles might also need a lower dose of warfarin.69  Carriers of two 
CYP2C9 alleles commonly referred to as *1, also known as the “wild type” 
or standard type, “are extensive metabolizers of warfarin.”70  The two 
common relevant CYP2C9 variants are referred to as CYP2C9*2 and *3.71  
The most common relevant VKORC1 variant is referred to as VKORC1 
3673 G>A (or -1639 G>A).72  These variants have become particular 
targets for genetic testing. 
With the proliferation of genetic data one might think that race would 
cease to play a significant role in studies of warfarin response.  Yet, as 
genetic studies have proliferated, so has the use of race and related 
categories to assess variable frequencies of particular polymorphisms in 
specific population groups.  Thus, numerous studies have observed that 
some relevant CYP2C9 and VKORC1 alleles vary in frequency across 
certain ethnic or racial groups.73  Usually these studies use such broad 
categories as “Asian,” “Caucasian,” “Hispanic” or “African-American,”74 
but some studies are more nation-specific, identifying allele frequencies and 
response, for example, in Swedes, Koreans, Iranians, Japanese, and 
Israelis.75  Ironically, there seems to have been an increase in such racial, 
 
PHARMACOGENOMICS 169, 176 (2008).  See generally Milo Gibaldi & Gerhard Levy, 
Pharmacokinetics in Clinical Practice: I. Concepts, 235 JAMA 1864, 1864 (1976) (defining 
pharmacokinetics as being “concerned with the study and characterization of the time course 
of drug absorption, distribution, metabolism, and excretion, and with the relationship of these 
processes to the intensity and time course of therapeutic and adverse effects of drugs”). 
 65. See Kim, supra note 55, at 140. 
 66. See Wu, supra note 64, at 176. 
 67. See Merck, The Merck Manuals Online Medical Library, Introduction: 
Pharmacodynamics (2007) (defining pharmacodynamics), http://www.merck.com/mmpe/sec 
20/ch304/ch304a.html. 
 68. See Mathews, supra note 62.  See also Wu, supra note 64, at 169. 
 69. Wu, supra note 64, at 169. 
 70. Kim, supra note 55, at 140. 
 71. Julie A. Johnson, Ethnic Differences in Cardiovascular Drug Response: Potential 
Contribution of Pharmacogenetics, 118 CIRCULATION 1383, 1384 (2008). 
 72. Id. 
 73. See, e.g., id. at 1384-85; Wu, supra note 64, at 169. 
 74. See, e.g., Wu, supra note 64, at 169. 
 75. See, e.g., Hyun-Jung Cho et al., Factors Affecting the Interindividual Variability of 
Warfarin Dose Requirement in Adult Korean Patients, 8 PHARMACOGENOMICS 329, 329 
(2007); P. Ghadam et al., VKORC1 Gene Analysis in an Iranian Warfarin Resistant Patient, 8 
J. BIOLOGICAL SCI. 691, 691 (2008); Kenji Nakai et al., Ethnic Differences in the VKORC1 
Gene Polymorphism and an Association with Warfarin Dosage Requirements in 
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ethnic, or nation-specific studies of allele frequencies in recent years as the 
significance of specific genetic variations has been more fully elaborated 
and characterized. 
IV.  LABELS, TESTS, AND “ETHNIC” PRODUCT DIFFERENTIATION 
By August 2007, enough data on the genetics of warfarin response had 
been published to convince the FDA to authorize a labeling change to 
Coumadin to explain how users’ genetics may affect their responses to the 
drug.76  In a conference call announcing the change, the FDA’s Lawrence 
Lesko noted that, “this marks the first time that such pharmacogenomic 
information has been included in a widely used drug . . . .  This means that 
personalized medicine is no longer an abstract concept, but has moved into 
the mainstream, where it is recognized as a factor in a product used by 
millions of Americans.”77  Or, as an article in the journal Medical Marketing 
& Media enthused, “The FDA rang in the era of personalized medicine with 
a labeling change on blood thinner warfarin cautioning that patients with 
either of two genetic variations might respond differently to the drug.”78 
Significantly, news reports of the FDA-mandated label change also 
noted some of its regulatory, legal, and commercial implications.  First, 
Jane Woodcock, deputy commissioner and chief medical officer of the FDA, 
emphasized that the labeling update was “not a directive to doctors to use 
genetic tests for warfarin therapy” since current clinical studies do not 
definitively support such a recommendation.79  This caution was warranted 
given the fact that no prospective clinical trials had yet been conducted 
comparing the outcomes of using genetic tests to guide warfarin dosing as 
compared to existing practices.80  It reflects well-established understandings 
of the FDA’s role of regulating drugs and not the practice of medicine.  
 
Cardiovascular Surgery Patients, 8 PHARMACOGENOMICS 713, 713 (2007) (assessing allele 
frequencies of Japanese and Israeli populations); Fumihiko Takeuchi et al., A Genome-Wide 
Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic 
Determinants of Warfarin Dose, PLOS GENETICS, Mar. 2009, at 1 (study identifying allele 
frequencies in Swedish patients), available at 
http://www.plosgenetics.org/article/info:doi/10.1371/journal. pgen.1000433. 
 76. Turna Ray, FDA Updates Warfarin to Explain Genetic Links to Response; Says Change 
Not Meant As ‘Directive’ for Doctors, GENOMEWEB DAILY NEWS, Aug. 16, 2007, 
http://www.genomeweb.com/fda-updates-warfarin-label-explain-genetic-links-response-says-
change-not-meant-. 
 77. Id. 
 78. Matthew Arnold, Warfarin Label Change Advises on Genetic Factors, MED. 
MARKETING & MEDIA, Aug. 16, 2007, http://www.mmm-online.com/Warfarin-label-change-
advises-on-genetic-factors/article/30045/. 
 79. Ray, supra note 76. 
 80. See Mathews, supra note 62. 
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Second, it also reflects a concern involving potential legal claims of 
malpractice liability.  A report in the Wall Street Journal noted that prior to 
the labeling change, a medical group called the Anticoagulation Forum 
wrote a letter to Dr. Lesko warning that doctors might place too much 
reliance on the genetic tests, and subsequently fail to monitor their patients 
effectively.81  The Anticoagulation Forum worries that some doctors might 
even hold off in starting a patient on warfarin until the doctors have the 
results of the test in hand.82  “The group asked that any new label ‘reflect 
the uncertainty’ so doctors wouldn’t be held liable in court for failing to do 
the tests.”83  Third, even without a directive to test, large insurers like Aetna 
consider such labeling changes when deciding whether to reimburse for a 
genetic test.84  The labeling change, thus, had significant implications for 
the growing industry of pharmacodiagnostics.  Indeed, since the labeling 
change, a number of companies have petitioned the FDA for approval of 
diagnostic kits that test for a variety of CYP2C9 and VKORC1 
polymorphisms related to warfarin response.85 
Numerous companies offer one form of genetic testing or another 
related to warfarin response.86  These range from smaller dedicated 
diagnostic companies such as Autogenomics, Nanosphere, and 
Osmetech,87 to new, large, full-service direct-to-consumer genomics 
companies such as 23andMe, DNA Direct, and deCODE genetics.88  These 
latter direct-to-consumer companies offer so-called “home brew” tests that 
do not require specific FDA approval to be offered to the public.89  
Additional companies offering such tests include ARUP Laboratories, 
Laboratory Corporation of America, Mayo Medical Laboratories, Kimball 
Genetics, PGXL Laboratories, Clinical Data, and Genelex.90 
 
 81. Mathews, supra note 62. 
 82. Id. 
 83. Id. 
 84. Ray, supra note 76. 
 85. See Ray, supra note 21. 
 86. Id. 
 87. Id. 
 88. Turna Ray, 23andMe Begins Reporting Three SNPs for Warfarin Sensitivity; Plans to 
Study Others, PHARMACOGENOMICS REP., Apr. 1, 2009, http://www.genomeweb.com/dxpgx/ 
23andme-begins-reporting-three-snps-warfarin-sensitivity-plans-study-others. 
 89. GenomeWeb News, CombiMatrix Forms Molecular Dx Unit to Perform Home-Brew 
Tests; Eyes Eventual FDA Clearance, GENOMEWEB DAILY NEWS, May 10, 2005, 
http://www.genomeweb.com/combimatrix-forms-molecular-dx-unit-perform-home-brew-tests-
eyes-eventual-fda-cl.  See also Genetics & Public Policy Center, Who Regulates Genetic Tests? 
(Feb. 27, 2006) (discussing federal regulation of genetic testing), http://www.dnapolicy.org/ 
policy.issue.php?action=detail&issuebrief_id=10. 
 90. Ray, supra note 21. 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
74 SAINT LOUIS UNIVERSITY JOURNAL OF HEALTH LAW & POLICY [Vol. 3:61 
In this crowded market, one basic way for a company to differentiate its 
product is to obtain FDA approval for its particular test, thereby certifying its 
clinical validity.91  A number of companies have obtained such approval, 
including Autogenomics, Nanosphere, Paragon Dx, and Osmetech.92  
Beyond this, companies are also highlighting their ability to provide 
distinctive services such as fast turnaround time, additional consultation, or 
even help with processing claims. 93  Finally, because there are numerous 
alleles, both of CYP2C9 and VKORC1, for which it is possible to test, some 
companies distinguish their tests by allele.94  The most commonly tested 
alleles are CYP2C9*2 and *3, and VKORC1 mutations at the -1639G>A 
positions.95  Nanosphere, for example, distinguishes its test in part by noting 
that it also tests at the VKORC1 1173C>T positions.96 
In the realm of allelic product differentiation, AutoGenomics has come 
up with race, or as it says “ethnicity,” as a means to make its product stand 
out in the crowd.97  It does this by looking at some of the less common 
CYP2C9 and VKORC1 alleles and evaluates how their frequencies vary 
across ethnic groups.98  As one news article on competition in the warfarin 
gene-testing market put it: 
AutoGenomics boasts that its INFINITI assay detects 15 2C9 and VKORC1 
variants, more than any other company in the market.  Most other warfarin 
sensitivity assays look for the 2C9 *2 and *3, and the 3673 (-1639G>A) 
VKORC polymorphisms. 
Among the 15 variants the INFINITI assay detects, several polymorphisms 
will be specific to particular ethnicities – such as the *4 variant identified 
exclusively among Japanese people and the 8773 SNPs in VKORC1 found 
in 21 percent of African Americans. 
 
 91. See id. 
 92. CENTERS FOR MEDICARE & MEDICAID SERV., PROPOSED DECISION MEMO FOR 
PHARMACOGENOMIC TESTING FOR WARFARIN RESPONSE (CAG-00400N) (2009), 
https://www.cms.hhs.gov/mcd/viewdraftdecisionmemo.asp?from2=viewdraftdecisionmemo.a
sp&id=224&. 
 93. Ray, supra note 21. 
 94. See Turna Ray, AutoGenomics’ Warfarin Test Wins FDA OK; Gauges Variants 
Competitors Don’t, PHARMACOGENOMICS REP., Jan. 30, 2008, http://www.genomeweb.com/ 
dxpgx/autogenomics%E2%80%99-warfarin-test-wins-fda-ok-gauges-variants-competitors-
don%E2%80%99t. 
 95. Id. 
 96. Ray, supra note 21. 
 97. See id. 
 98. Id. 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
2009] BEYOND BIDIL 75 
Therefore, in marketing its test, AutoGenomics will likely specifically target 
certain ethnic groups, in addition to widely promoting it for the 200,000 to 
500,000 patients who get initiated on warfarin each year.99 
AutoGenomics is a privately held company, based in Carlsbad, 
California.100  Its mission is “to empower clinical laboratories with an 
automated cost effective solution to perform molecular testing that will 
significantly enhance work flow, cost efficiency, quicker turn-around time 
and result with enhanced patient care.”101  AutoGenomics offers an array of 
genetic tests on its website.  Many are currently for research use only (RUO), 
meaning they have not obtained FDA approval.102  It currently markets four 
FDA-approved tests, including a Warfarin Assay product.103  This particular 
assay, however, only covers the common CYP2C9*2 and *3 variations, and 
the VKORC1 3673 (-1639G>A) variant.104  The assay is not marketed with 
explicit reference to ethnicity.105 
AutoGenomics also has an extended “Warfarin XP” assay which tests for 
six different CYP2C9 variants and eight VKORC1 variants, but it is not yet 
FDA approved, so it is still only marketed for research use.106  Nonetheless, 
while its application for FDA approval of its basic warfarin gene test was still 
pending, the AutoGenomics website was rife with information on differing 
allele frequencies across ethnic groups and highlighted the Warfarin XP 
assay’s distinctive abilities to test broadly across an array of ethnic 
groups.107 
One AutoGenomics webpage, for example, ran with the title caption, 
“Warfarin XP: Enhanced Ethnic Characterization.”108  The expanded panel 
 
 99. Id. (emphasis added). 
 100. AutoGenomics, About Us, http://www.autogenomics.com/1/aboutUs.php (last visited 
Jan. 06, 2010). 
 101. Id. 
 102. AutoGenomics, INFINITI® Test Menu (RUO), http://www.autogenomics.com/1/RUO_ 
main.php (last visited Dec. 28, 2009). 
 103. Id. 
 104. AutoGenomics, INFINITI® Warfarin Assay (IVD), http://www.autogenomics.com/1/ 
pharma_warfarinassay.php (last visited Jan. 06, 2010). 
 105. See id. 
 106. AutoGenomics, INFINITI™ CYP450 2C9-VKORC1, http://www.autogenomics.com/1/ 
pharma_2C9.php (last visited Jan. 06, 2010). 
 107. AutoGenomics, Home Page, http://www.autogenomics.com/1/ (last visited Jan. 06, 
2010).  After FDA approval was obtained AutoGenomics has updated its website and no 
longer contains pre-approval information.  See Ray, supra note 21 (explaining that before 
FDA approval, AutoGenomics claimed INFINITI assay detected several polymorphisms across 
ethnicities and would likely market the assay towards specific ethnic groups). 
 108. AutoGenomics, Warfarin XP: Enhanced Ethnic Characterization, http://www.auto 
genomics.com (last visited July 14, 2008) (no longer available); see also AutoGenomics, Data 
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test explicitly linked genetics to ethnicity.  In a section discussing the “clinical 
relevance” of the test, AutoGenomics discusses the frequency of certain less 
common variants directly in terms of frequency in “Japanese,” “African-
Americans,” and “Caucasians.”109  Here is a clear example of when specific 
alleles are identified and testable yet a company still uses race to 
characterize the product.  Yet, why would AutoGenomics continue to use 
race if the gene has already been identified?  Certainly it is the gene 
variants, not race, which make the difference in clinical response.  It 
becomes evident that AutoGenomics is layering ethnicity onto its more basic 
Warfarin Assay product in order to differentiate its test and expand its 
market share.  Most companies, including AutoGenomics, will test for the 
three most common genetic variants affecting warfarin response.110  
Ethnicity here provides AutoGenomics the basis for offering a second test 
that covers those three common variants plus an additional eleven 
variants.111  The ethnicities identified also conveniently correspond to major 
racial groups—Asian (assuming Japanese comes to be taken as a stand-in 
for “Asian”), African (or African American), European (Caucasian).  Who 
might want this test then?  Apparently everyone in Japan, the United States 
(with the exception of Native Americans), and Europe—i.e. the world’s 
major medical markets—comprise the targeted population.  It might seem 
at first blush that developing a test for less common alleles might narrow 
one’s market, but when bundled with the test for common alleles and 
layered with racial identities, it becomes a potential means to capture 
greater market share. 
The salience of race in AutoGenomics’ marketing strategy is most 
evident in a 2008 PowerPoint presentation from its website, titled “Infiniti™ 
Warfarin XP: Because Ethnic Diversity Matters When Dosing With Warfarin.” 
112  The presentation begins with a slide noting the importance of the recent 
FDA re-labeling of warfarin for genetic data.113  It then discusses the 
variation across race of the particular CYP2C9 and VKORC1 alleles for 
which it tests, noting that its product is “THE ONLY TEST AVAILABLE THAT 
INCLUDES ALL RELEVANT VARIANTS!”114  The inevitable conclusion is that 
“[d]etecting 2C9 variants in addition to [the common] *2, *3 is essential for 
 
Sheet, http://www.autogenomics.com/1/DataSheets/warfarinxp/dosingAlgorithms.pdf (last 
visited Jan. 06, 2010). 
 109. AutoGenomics, 2C9-VKORC1 Pharmacogenetics, http://www.buhlmannlabs.ch/files/ 
documents/molecular/autogenomics/flyer_2c9-vkorc1.pdf (last visited Jan. 06, 2010). 
 110. Ray, supra note 94. 
 111. Id. 
 112. AutoGenomics, Infiniti™ Warfarin XP: Because Ethnic Diversity Matters When Dosing 
with Warfarin 1 (on file with author). 
 113. Id. at 2. 
 114. Id. at 23. 
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a broader identification of high risk warfarin metabolizers in several ethnic 
groups.” 115  The emphasis here is on the need for an expanded panel 
testing for more variants.  Ethnicity provides a rationale for offering an 
expanded test panel that differentiates the AutoGenomics test from others 
on the market. 
One of AutoGenomics’ most explicit uses of race to differentiate its 
product occurs in the following slide:116 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
According to this slide, tests other than AutoGenomics Infiniti platform 
would miss relevant genetic variants in “virtually ALL non-caucasian [sic] 
patients; Asian, African American, Chinese, Japanese, Hispanic, etc., would 
be missed using a panel limited to these variants.”117  The slant here is quite 
striking; it makes racial and ethnic identification appear to be essential to 
finding relevant genetic variants.  In fact, the common *2, *3, and 1173 
variants mentioned in this slide occur in all of these groups at differing 
frequencies.118  The only possible way to make sense of its claim about 
“missing” “non-Caucasians” is to assume it is referring to the patients with 
the rarer alleles who would be missed by products that do not test for them.  
 
 115. Id. at 24. 
 116. Id. at 28. 
 117. Id. 
 118. See Johnson, supra note 71, at 1384. 
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In developing its test, therefore, AutoGenomics is not just looking for genes; 
it is looking for racial and ethnic groups to whom it can market its product.  
This is also evident in the slide’s reference to variations “specific” to Asians 
and African Americans.  (Ironically, the reference to African American-
specific variants also are said to be of significance to “Caucasians”).  
AutoGenomics is attempting to translate racially identified gene frequencies 
into racially identified market share.  In this case, finding specific genes has 
not led researchers to leave race behind.  To the contrary, it has led to the 
rise of new ways to exploit race in the biomedical marketplace. 
Marketing based upon race also provides rationale for its commercial 
viability.  If AutoGenomics simply tested for rare alleles, e.g. CYP2C9 *5, *6 
or *11, it might have difficulty gaining acceptance in the market against 
products that tested for the most common significant variants.  Simply 
adding an array of rare alleles that only marginally increases the odds of 
finding a significant genetic variation could easily make AutoGenomics’ test 
appear needlessly complex.  Yet, by tying rare alleles to specific ethnic or 
racial groups, AutoGenomics provides a hook to draw in potential 
consumers.  You might not know whether you have a rare allele but you do 
know if you are black, white or Asian.  A product that says it tests for a rare 
allele that is found primarily in the individual’s racial or ethnic group is one 
he or she may choose despite its rarity.  AutoGenomics thus uses race not to 
identify alleles but rather to induce consumers to identify their own race or 
ethnicity (and hence themselves) with certain alleles.  AutoGenomics frames 
the test so that African, Asian, or European race becomes identified in the 
consumer’s mind with allele frequency.  Beyond this, for the product actually 
to succeed in the market place, biomedical professionals and insurance 
companies must similarly identify race with genetics in warfarin response.  
Through its product development and marketing strategies, AutoGenomics 
is not only selling a pharmacogenomics assay, it is producing a conception 
of race as genetic. 
Ironically, following its 2008 approval of AutoGenomics’ basic warfarin 
assay that tested only for the three most common CYP2C9 and VKORC1 
variants, the FDA required AutoGenomics to remove all material of “clinical 
relevance” associated with its various RUO assays from its website.119  The 
Warfarin XP expanded panel is not yet FDA approved, i.e. it is for “Research 
Use Only.”120  All of AutoGenomics’ references to race appeared under 
“Clinical Relevance” headings for Warfarin XP and have since been 
removed from the website.  Similarly, the “Because Ethnic Diversity 
Matters . . .” presentation has also been removed from the website.  
 
 119. Email from Anand Vairavan, Marketing Manager and personalized Medicine 
Specialist for AutoGenomics, (May 20, 2009) (on file with author). 
 120. AutoGenomics, supra note 106. 
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Nonetheless, Anand Viaravan, Marketing Manager and Personalized 
Medicine Specialist for AutoGenomics, insists that “we still absolutely believe 
that Ethnic Diversity Matters when developing genetic tests to help with 
Warfarin dosing.”121  Indeed, he notes that “we still do offer this assay and 
sell more of the Expanded Panel assay as opposed to the [FDA approved] 
IVD assay.”122 
Here, regulatory approval extracted a trade-off among tactics for 
product differentiation.  On the one hand, AutoGenomics gained the 
legitimacy and distinction conferred by the FDA approval.  On the other 
hand, it has since been forced to downplay the racial aspect of the 
Expanded Assay at least until it gets FDA approval for that test as well.  
Nonetheless, AutoGenomics’ commitment to racialized marketing of its 
product remains clear and the expanded assay continues to be a more 
profitable test.  Indeed, AutoGenomics has licensed the technology to 
several companies in Europe, one of which, the Swiss Company Buhlmann 
Laboratories, AG, continues to post AutoGenomics’ slides on its website 
describing the expanded assay with race-specific information.123  
AutoGenomics thus is working to minimize the impact of this trade-off and 
maintain its commitment to producing and capturing a racialized market. 
There is an additional and deeper irony embedded in AutoGenomics’ 
marketing strategy.  At first glance, the use of race to help target therapies, 
whether for warfarin or for BiDil, may appear to be a means to redress 
historically race-based inequities in the delivery of health care in the United 
States.  Certainly, taking account of the distinct needs and concerns of 
historically disadvantaged minority communities is a laudable and worthy 
goal.  The Civil Rights Act of 1964, the Voting Rights Act of 1965, and the 
Fair Housing Act of 1965 all took race into account in fashioning remedies 
for historical race based inequities.124  In the realm of biology, however, the 
use of race becomes far more problematic than in other areas of past 
discrimination such as employment, voting, or housing.  As biologist Anne 
Fausto-Sterling notes, “Only rather slowly has the medical community 
realized that what appears at first to be an inclusive move—mandating 
participation by racially and sexually distinguishable groups in drug and 
other trials—might have a scorpion’s sting, diverting attention from 
socioeconomic explanations of (and remedies for) health disparities.”125  
 
 121. Email from Anand Vairavan, supra note 119. 
 122. Id. 
 123. AutoGenomics, supra note 109. 
 124. See Eric K. Yamamoto et al., Dismantling Civil Rights: Multiracial Resistance and 
Reconstruction, 31 CUMB. L. REV. 523, 530-31 (2001). 
 125. Anne Fausto-Sterling, Refashioning Race: DNA and the Politics of Health Care, 
DIFFERENCES, Fall 2004, at 1, 3. 
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How much more powerful might this dynamic prove when driven by 
commercial considerations of developing a market niche for a biomedical 
product? 
V.  RACE, COMMERCE, AND REGULATORY CLASH 
Market differentiation is one type of commercial imperative driving the 
use of race in biomedical research and product development.  More 
straightforward concerns for economy and efficiency may also be providing 
further impetus for continuing to use race in the face of genetic discovery.  
Such concerns are alluded to in a study by Yen-Revollo et al., which notes 
that using race as a surrogate is also appealing “because personal 
genotyping is cost prohibitive.” 126  Simply stated, it is cheaper to identify a 
patient by race than by genotype.  Beyond this, it turns out race can be 
economically relevant not only as an alternative to genotyping but also as a 
complement to it.  Thus, for example, a 2008 policy statement on gene 
testing for warfarin response issued by the American College of Medical 
Genetics (ACMG) states: 
CYP2C9*2 and *3 are found in the major racial groups, but with different 
allelic frequencies.  These alleles should be tested in all individuals.  There 
are also several rare alleles of CYP2C9 alleles that have different 
frequencies in different ethnic populations, and some alleles are 
preferentially found in only certain racial groups.  Some CYP2C9 alleles, 
such as CYP2C9 *5, *6, and *11, are preferentially found in African-
descendent populations at low allele frequencies, but are not found in 
Asian-descendant populations.  On the other hand, the rare CYP2C9 *4 
polymorphism has only been reported in individuals from Asia.  The 
decision to test for polymorphisms other than CYP2C9 *2 and *3 should be 
based on the populations being tested by a laboratory and the capability to 
make patient management decisions informed by these less-frequently 
encountered alleles.127 
Race is front and center here right alongside specific genetic variation.  
Given the nature of genetic variation, however, it will always be possible to 
find certain genetic variations that occur at differing frequencies across 
racial groups.128  For example, studies of a particular VKORC1 variant have 
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found a range of frequencies in European populations from 39% in 
“Swedish” to 52% in “Spanish.”129  One comprehensive review article found 
frequency variation for having at least one CYP2C*2 allele in different 
“Caucasian” populations ranging from 0.9% to 20.4%, and a range for 
“Africans” from 0.0% to 8.7%.130  On one hand, there certainly is a 
difference in frequency between Africans and Caucasians.  On the other 
hand, there is also significant overlap, and the overall variation within the 
Caucasian group seems to dwarf that between Africans and Caucasians.  
The question is which differences the researchers and product developers 
choose to make matter and how. 
A sense of how these choices are made is provided by an examination 
of the studies cited by the ACMG report to support its recommendation to 
take race into account.  Thus, to support its assertion that “[s]ome CYP2C9 
alleles, such as CYP2C9 *5, *6, and *11, are preferentially found in 
African-descendent populations at low allele frequencies, but are not found 
in Asian-descendant populations,” 131 the report cites an article by Guyong 
Tai et al., “In-Vitro and In-Vivo Effects of the CYP2C9*11 Polymorphism on 
Warfarin Metabolism and Dose.”132  As is evident from the title, this study 
discusses only the CYP2C9*11 polymorphism and says nothing about 
frequencies for the *5 and *6 alleles.133  Moreover, this was a study of 303 
“Caucasians” and 101 “African-Americans;” it says nothing about allele 
frequencies in Asian populations.134  Additionally, to support its assertion 
that “the rare CYP2C9 *4 polymorphism has been found only in individuals 
from Asia,”135 the ACMG report cites an article titled, “A Case Report of a 
Patient CarryingCYP2C9*3/4 Genotype with Extremely Low Warfarin Dose 
Requirement.”136  As is evident again from the title, this study was a case 
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report of a single Korean patient.137  The report itself notes, “This is the first 
report of a Korean patient with the CYP2C9*3/*4 showing warfarin 
intolerance.  The CYP2C9*4 allele including 1076T>C (Ile359Thr) has 
been reported in only one Japanese subject.”138  Thus, the ACMG has taken 
a report of one Korean individual that also cites one additional Japanese 
subject and expanded into a technically accurate, but highly misleading, 
assertion that this allele is only found in “individuals from Asia.”  There may 
well be studies that provide better support for the ACMG’s assertions, but 
the studies ACMG cites certainly are not sufficient.  They only casually add 
to an accumulating sort of folk wisdom or common sense in the medical 
community that promotes the continued relevance of race alongside the 
development of specific genetic information. 
The basis for making the choice to frame allele frequency data in terms 
of race takes on a distinctly economic feel when considered in light of the 
statement’s overall purpose of identifying which groups should get which 
tests.  In the ACMG report, race becomes relevant here at the margins, 
where allele frequencies are low and variable across racially defined 
population groups.139  The ACMG, in effect, suggests using race as a 
screening mechanism to determine which individuals should get which 
genetic tests; yet, multiplex assays such as those offered by AutoGenomics 
(not to mention those now being offered by such genetic testing behemoths 
as 23andMe) are currently able to test efficiently for a range of alleles at 
once.140  The only apparent reason remaining for preferentially assigning 
tests by race therefore appears to be economic, rather than scientific, 
efficiency.  If testing for more alleles costs more, then race may be used to 
perform a sort of economic triage to focus on those for whom the test is 
most likely to produce a useful result. 
Lawrence Lesko and other senior FDA officials have echoed the logic of 
the ACMG’s report, stating, for example, that: 
The type of genomic data (e.g., which alleles, what genotypes) that needs to 
be evaluated, and when, is one of the critical issues in drug development 
and regulatory review.  In some cases, consideration of racial/ethnic 
differences in the distribution of various alleles with no or reduced metabolic 
activity in the evaluation of dose-response relationships is important.141 
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The article goes on to specify CYP2C9 as one of the “recommended 
polymorphic alleles to measure in specific population groups.”142  These 
groups, not surprisingly, are racialized as “Caucasians,” “African 
Americans,” and “Asian Americans.”143  For the FDA, then, race remains 
not only a legitimate but a “critical factor” in evaluating drug dose 
response—again, even as specific genes are being identified.144  In this 
conceptualization of the promise of pharmacogenomics, genes are not 
replacing race, they are complementing race. 
All of this brings us back to AutoGenomics and its marketing campaign 
for its Warfarin XP assay built around the proposition that “Ethnic Diversity 
Matters.”145  The commercial value of this product is intimately tied to the 
statements of biomedical professionals, such as the ACMG, and federal 
regulators, such as Lesko at the FDA.  Research, regulation, and commerce 
are thus mutually implicated in producing an understanding of race as 
relevant to pharmacogenomics and in constructing consumers and clinicians 
who identify race with genetics when making medical decisions. 
Research, regulation, and commerce, however, are not monolithic 
phenomena.  As already discussed above, there is ongoing debate among 
researchers concerning the utility of race in pharmacogenomics.  There is 
also something of a regulatory clash between the FDA and the Centers for 
Medicaid and Medicare Services (CMS) concerning warfarin testing.  The 
clash grows out of the 2007 FDA labeling change for warfarin that specified 
the significance of specific alleles.146  The labeling change gave urgency to 
efforts to develop viable genetic dosing algorithms and also provided a 
great impetus to companies to develop and market genetic tests.147  A 
recent market report from MarketResearch.com titled, “Pharmacodiagnostics 
and Personalized Medicine 2009 (Markets, Challenges, Forecasts and Key 
Players)” discusses warfarin and the economic significance of the FDA label 
change at length.148 
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Gene tests for warfarin response average between $300 and $500 per 
test.149  Paying for such tests obviously is central to the test’s commercial 
success, and central to payment is the issue of insurance coverage.  The 
problem for companies that offer genetic tests is that the FDA 
recommendation is based on the clinical validity of the tests while insurance 
coverage tends to be based on considerations of clinical utility and related 
concerns for cost-effectiveness.150 
The clinical utility of genetic testing for warfarin dosing has not yet been 
established to the satisfaction of numerous insurers.  One article in the Wall 
Street Journal noted that “major insurers such as Aetna Inc., WellPoint Inc. 
and Cigna Corp.” do not cover the costs of such tests, possibly because 
“[s]ome specialists say testing hasn’t been proved to reduce the risks of the 
drug.” 151  Indeed, even such influential studies as that conducted by the 
IWPC were retrospective and did not measure whether incorporating genetic 
data into dosing algorithms materially reduced adverse drug events 
(ADEs).152  As University of Washington professor, Ann Wittkowsky, said of 
the FDA labeling decision, “It is fascinating science, but it is not yet ready for 
prime time [sic].”153 
Similarly, a 2008 report of the Secretary of Health and Human Services’ 
Advisory Committee on Genetics, Health and Society (SACGHS) titled 
“Realizing the Potential of Pharmacogenomics: Opportunities and 
Challenges” while referring to the use of CYP2C9 and VKORC1 testing to 
guide warfarin dosage as an early application of pharmacogenomics, 
nonetheless indicated that “much of the valuable information about PGx 
[pharmacogenomics] is in the form of early scientific discoveries.  Although 
this information has the potential to be useful, its clinical utility is not yet well 
understood.”154  Francis Collins, shortly after he stepped down as Director 
of the National Human Genome Research Institute, stated his belief that 
researchers still did not “have the right type of evidence ‘to enable a clear 
statement to providers about whether this kind of genetic testing ought to be 
done prospectively before trying to prescribe this drug with all of its 
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complications.’”155  Even the FDA’s own deputy commissioner and chief 
medical officer, Janet Woodcock, noted that they would “have to wait for 
outcomes data” before actually changing the label to mandate genetic 
testing.156 
So it was that in May 2009 that CMS announced its intention to deny 
Medicare coverage for pharmacogenomic testing that aims to predict 
warfarin responsiveness, stating that it “believes that the available evidence 
does not demonstrate that [such testing] improves health outcomes in 
Medicare beneficiaries.”157  CMS held out the possibility that coverage 
might be granted in the future, but only for a prospective, randomized 
clinical trial.158 
In the January 2009 issue of the Annals of Internal Medicine, a timely 
study was published questioning the cost-effectiveness of using 
pharmacogenomics information in warfarin-dosing.159  Dr. Mark Eckman, 
the lead author on the study, pointedly criticized a 2006 study conducted 
jointly by the American Enterprise Institute and the Brookings Institution that 
estimated an annual savings of $100 million to $2 billion from integrating 
genetic testing into warfarin therapy,160 as “optimistic” in its assumptions.161  
The AEI-Brookings report was actually conducted by FDA staff162 and had 
been posted by the FDA to support the drive toward incorporating 
pharmacogenomic data in drug submissions.163  It was also cited by 
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diagnostic companies, such as Iverson Genetic Diagnostics, Inc,164 and 
Osmetech,165 to support the marketing of their products. 
As one might expect, the CMS announcement was not well received by 
companies offering genetic tests, especially given the fact that many private 
payors follow CMS’s lead when determining whether to cover new 
technologies.166  Ramanath Vairavan, senior VP of sales and marketing for 
AutoGenomics, opined: 
This illogical decision perhaps has been influenced by the lobbying of big 
pharma, that in spite of numerous prospective studies and publications that 
have clearly shown the benefit for genetic testing and the FDA relabeling of 
the drug, CMS has succumbed into making a contradictory decision that will 
certainly impact patient well being and the cost of healthcare.  As a 
manufacturer of the test we appeal to CMS to revisit this controversial 
decision at the earliest.167 
Vairavan’s concern regarding “big pharma” is notable and highlights 
the fact that the pharmcogenomics industry is not monolithic.  He is 
apparently alluding to one of the great tensions at the heart of 
pharmacogenomics: on one hand, it is understood as the wave of the 
future, saving money and improving therapies.  On the other hand, it 
involves narrowing the market for a drug down to smaller and smaller 
subgroups that show the best response. 
One of the little known facts about blockbuster drugs is that they are 
“typically effective in only forty to sixty percent of the patient population.”168  
“By identifying true responders, pharmacogenomics also threatens to reduce 
substantially (often by more than 50%) the potential consumer base for any 
given drug.”169  One study of data from the Physician’s Desk Reference 
found “[t]he percent of responders range from a low of 25% (oncology 
products) to a high of 80% (Cox2 inhibitors), with the majority of drugs 
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having a responder rate of 50-60%.”170  The marketing model for genetic 
tests ultimately depends on the ability to use genomics to identify which 
subjects should get which drugs—i.e. to narrow the market for specific 
drugs.  The more pharmacodiagnostics companies are able to identify 
genes that correspond with drug response, the greater will be the market for 
their products.  Each success for a company like AutoGenomics represents a 
potential threat to big pharmaceutical companies marketing blockbuster 
drugs to large, undifferentiated populations.  Yet, one review of the 
comments submitted to CMS before it announced its intentions found that 
most of those opposing coverage (about eighteen percent of the total) were 
“professional organizations, payors, and some healthcare 
providers . . . .”171  Those with the most immediate interest in the CMS 
decisions appear to have been those with an immediate stake in the 
payment for diagnostic tests.172 
In the aftermath of the CMS decision, the Center for Medicine in the 
Public Interest (CMPI) announced plans to develop a proposal outlining 
areas where the FDA and CMS “can harmonize the way they evaluate 
outcomes and guide treatment . . . .” 173  The CMPI is a conservative, free-
market oriented group associated with the Pacific Research Institute, a think 
tank founded in 1979 whose stated vision is the promotion of “the principles 
of individual freedom and personal responsibility [which], [t]he Institute 
believes . . . are best encouraged through policies that emphasize a free 
economy, private initiative, and limited government.”174  Since the plans 
were announced, in part, as a response to the CMS decision, it seems 
evident that the CMPI is casting the CMS as an impediment to product 
development and hence the “harmonization” sought by the CMPI primarily 
involves getting CMS to follow the more industry-friendly FDA in its attitude 
toward genetic testing for warfarin.175 
Hope is on the horizon for pharmacodiagnostic companies, however, as 
prospective studies of the clinical utility of pharmagenomic dosing 
algorithms are being designed and carried out.  Prominent among these is a 
trial known as COAG (Clarification of Optimal Anitcoagulation through 
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Genetics) directed by the National Heart, Lung, and Blood Institute.176  The 
study will enroll 1,200 patients and cost nearly ten million dollars.177  In 
February 2009, Raynard Kington, then acting Director of the NIH asserted, 
“These efforts showcase NIH’s firm commitment to building a future of 
personalized medicine—a future in which doctors will be able to prescribe 
the optimal dosage of medicine for each patient right from the start.”178 
Race does not seem to have played much of a role in the CMS decision 
or subsequent debates about the merits of insurance coverage for genetic 
tests.  In the minutes of the February 2009 CMS meeting discussing genetic 
testing, there is barely a mention of race or ethnicity.179  Race seems to be 
much more important to FDA officials, such as Lawrence Lesko or Robert 
Temple, who see it as a means to drive their agenda of pursuing 
pharmacogenomic drug development, than it is to CMS officials (and 
private insurers) who are focusing on the more contained, and less easily 
racialized issues of clinical utility and cost-effectiveness.  Indeed, warfarin is 
front and center as a poster child for the FDA’s “Critical Path Initiative,” a 
major effort begun in 2004 to “stimulate and facilitate a national effort to 
modernize the sciences through which FDA-regulated products are 
developed, evaluated, and manufactured.”180  The first of a series of 
interviews posted on the FDA website to explore Critical Path projects 
focused on warfarin.181  Race is useful to the FDA to the extent that it 
furthers the progress of drugs such as warfarin towards the promise of 
“personalized medicine,” and thus validates efforts such as the Critical Path 
Initiative.182  CMS, in contrast, does not have any particular institutional 
imperative to use race in making coverage determinations. 
VI.  THE CONTINUING VALUE OF RACE IN BIOTECHNOLOGY PATENTS 
Race has re-entered the regulatory scene, however, in proceedings 
before the PTO.  Interestingly, it is not the genetic-testing companies, such 
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as AutoGenomics, who are using race in their patents—their patents tend to 
cover the technical specifications of their assay platforms (the actual 
apparatus conducting the tests) with race being reserved for certain 
marketing efforts.  Rather, it is certain warfarin researchers themselves who 
have introduced race into the realm of intellectual property.  On December 
21, 2005, Yuan-Tsong Chen, Hsiang-Yu Yuan, and Jin-Jer Chen filed a 
patent application titled “Genetic Variants Predicting Warfarin Sensitivity.”183  
The lead inventor, Yuan-Tsong Chen, is a Distinguished Research Fellow at 
the Genomics Research Center and Director of the Institute of Biomedical 
Sciences at the Academia Sinica in Taipei, Taiwan.184  He is also a Professor 
in the Department of Genetics at Duke University in Durham, North 
Carolina.185  The other inventors were also associated with the Academia 
Sinica at the time of the application, and the patent rights have been 
assigned to that institution.186  The Academia Sinica is a member of the 
IWPC and is credited with supplying data to the dosing algorithm study 
published so prominently in the New England Journal of Medicine in 
February, 2009.187 
The Abstract of the patent application states, “We discovered that a 
polymorphism in the promoter of the VKORC1 gene is associated with 
warfarin sensitivity.  This polymorphism can explain both the inter-individual 
and inter-ethnic differences in warfarin dose requirements.”188  The Claims 
section includes the following: 
1. A method of determining the dose range of a warfarin for a subject, 
comprising investigating the sequence of the promoter of the VKORC1 gene 
of the subject.” 
* * * 
9. The method of claim 1 wherein the subject is an Asian. 
10. The method of claim 1 wherein the subject is a Caucasian. 
11. The method of claim 1 wherein the subject is an African, African 
American, or Hispanic.189 
 
 183. Genetic Variants Predicting Warfarin Sensitivity, U.S. Patent Application No. 
20060166239 (filed Dec. 21, 2005). 
 184. Genomics Research Center, Academia Sinica, Yuan-Tsong Chen, 
http://www.genomics.sinica.edu.tw/index.php?option=com_content&view=article&id=96&Ite
mid=211&lang=en (last visited Jan. 06, 2010). 
 185. Id. 
 186. Genetic Variants Predicting Warfarin Sensitivity, supra note 183. 
 187. Int’l Warfarin Pharmacogenetics Consortium, supra note 53, at 753-54, 763. 
 188. Genetic Variants Predicting Warfarin Sensitivity, supra note 183 (emphasis added). 
 189. Id. (emphasis added). 
SAINT LOUIS UNIVERSITY SCHOOL OF LAW 
90 SAINT LOUIS UNIVERSITY JOURNAL OF HEALTH LAW & POLICY [Vol. 3:61 
The mention of race in the Claims section is particularly significant 
because the claims specify the legally operative scope of the patent, defining 
the formal legal “metes and bounds” of the territory covered by an 
invention.190  The force and authority of the United States government is thus 
conscripted into legitimating the use of race in relation to genetics in a 
manner that implies that race itself is genetic.  The basis for making such 
race-specific claims is found in studies of allele frequencies that vary across 
population groups.  Such variation is here reductively solidified into rigid 
racial differences that are then given the imprimatur of the state through the 
potential grant of patent protection. 
A news report on Academia Sinica and its role in the IWPC noted that 
there is a follow-up study of 600 patients in Taiwan in order to verify the 
predictive accuracy of the model.191  One of the Academia Sinica 
researchers asserted, “The result of the study on the island is significant in 
that it will serve as the dosing guideline for people of ethnic Chinese origin.  
This is the largest community in the world.”192  The report goes on to note: 
The research efforts may turn out to be profitable as well.  In 2005 
Academia Sinica created a spin-off business called PharmiGene Inc., which 
focuses on the creation of personalized medicine products.  The company 
has already used the scientific knowledge gained by Academia Sinica to 
manufacture several gene-detection kits, including a warfarin dosing 
prediction model developed in 2005.193 
With PharmiGene and its race-specific patent, Academia Sinica is 
positioning itself to sell its warfarin tests to “people of ethnic Chinese 
origin,” not only the largest “community” in the world, but also the largest 
potential market.  Race, in short, persists as a viable basis for framing and 
capturing a pharmacogenomic market. 
Importantly, an average patent application takes at least two years to 
process.194  As Academia Sinica’s race-specific patent is working its way 
through the PTO (known as the “patent prosecution” process) it has 
encountered some problems.  To obtain patent protection for inventions, all 
patent applications must meet several statutory requirements.  The most 
prominent of these are known as “useful[ness]” (or utility),195 “novelty,”196 
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“non-obvious[ness],”197 and “specification.”198  In January 2009, the patent 
examiner rejected certain claims in the application as obvious and 
anticipated (i.e. not “novel”) by two patent applications filed by University of 
Washington researcher Mark Rieder (also a member of the IWPC)—
particularly the second application, #20080057500 (referred to as “Rieder 
II”).199  The Rieder application (a continuation of an earlier patent filed on 
October 18, 2004) was titled “Methods and Compositions for Predicting 
Drug Responses.”200  The application directly referenced the VKORC1 gene 
and warfarin response, stating in the abstract, “the present invention 
provides methods and compositions for determining individualized Warfarin 
dosages based on genotype of DNA polymorphisms and haplotypes derived 
from them in the VKORC1 gene.”201  Given Academia Sinica’s patent 
application’s explicit focus on VKORC1, this presented something of a 
problem. 
In response, Yuan-Tsong Chen filed an “Inventor’s Declaration” setting 
forth his reasons why the Rieder application did not negate his 
submission.202  He placed race at the center of his argument as he asserted, 
although only 4% [of] Caucasians carry the haplotypes [a group of linked 
genes] unrelated to warfarin response, i.e., H3-H6, these haplotypes 
constitute as high as 39% of the African-American population and as high 
as 19% in Hispanic Americans.  As another example, the total frequency of 
H3-H6 is 20% in ethnic groups other than Caucasians, African-Americans, 
Asians, and Hispanic-Americans.  These teachings clearly indicate that 
haplotypes H3-H6, which, according to Rieder II, are unrelated to warfarin 
response, CANNOT be ignored in the whole human population.203 
Chen is here explicitly using race to show the relevance of haplotypes H3-
H6 and thus differentiating his patent application from Rieder’s.  He adds 
race to make his claims appear novel and non-obvious.  The motivation 
here is not scientific, but legal and commercial.  The connection between 
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genes and race primarily serves the purpose of obtaining patent protection, 
not of furthering science. 
VII.  CONCLUSION 
Hearkening back to the role of patents in the case of BiDil, we can see 
how the cases of Bystolic (nebivolol) and warfarin response testing are both 
similar and different.  The story of BiDil involved the use of race to re-
capitalize the value of existing generic drugs.  The need to create a 
patentable product in order to convince corporate backers of the drug’s 
viability as a commercial product led to using race as a frame for 
interpreting existing science, developing clinical trial protocols, compiling 
regulatory filings, and designing marketing campaigns.  Patenting and 
marketing strategies mutually incentivized the use of race independent of 
any specific scientific or medical utility.  The new nebivolol patent 
application indicates a BiDil-like strategy to use race to extend patent life.  
In contrast, the Academia Sinica patent application process has not directly 
involved the reconfiguration of an existing product as racial in order to 
extend patent life, but it does show how race can be used to differentiate 
one product or process from another as a potential means to obtain initial 
patent protection.  Both models involve the exploitation of race in order to 
enhance the commercial value of scientific research by creating race-
specific market-niches for products.  The story of warfarin testing further 
demonstrates that even after specific genes for drug response are identified, 
race continues to be commercially useful as a means to gain patent 
protection and carve out niches in a crowded marketplace.  Biotechnology 
firms and biomedical professionals thus continue to embrace race as a 
central component of patenting and marketing strategies, even after it has 
ceased to serve any scientific purpose. 
 
